Literature DB >> 24872472

Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure.

Michael Ried1, Karla Lehle2, Reiner Neu3, Claudius Diez3, Patrick Bednarski4, Zsolt Sziklavari5, Hans-Stefan Hofmann6.   

Abstract

OBJECTIVES: The effects of cisplatin on the lung parenchyma during hyperthermic intrathoracic chemotherapy perfusion have not been analysed in detail. The objective of this study was to evaluate both the concentration and depth of the penetration of cisplatin in human lung tissue after hyperthermic exposure under ex vivo conditions.
METHODS: This experimental study was approved by the local ethics committee. Twelve patients underwent pulmonary wedge resections after elective thoracic lobectomies were performed (resected lobe), and the lung tissue (approximately 1-2 cm(3)) was incubated (in vitro) with cisplatin (0.05 mg/ml; 60 min, 42°C). Subsequent tissue beds (depth, 0.5 mm; median weight, 70-92 mg) were prepared from the outside to the middle, and the amount of cisplatin per tissue weight was analysed using atomic absorption spectrometry. Afterwards, the penetration of cisplatin depth was calculated and related to the different concentrations per tissue.
RESULTS: Cisplatin penetrated into the human lung tissue after ex vivo hyperthermic exposure. The median amount of platinum [nmol cisplatin/g lung tissue] decreased significantly (P ≤ 0.05) depending on the penetration depth: 32 nmol/g (1 mm), 20 nmol/g (2 mm) and 6.8 nmol/g (4 mm). The calculated median concentrations of cisplatin (µg/ml) were 2.4 µg/ml (1 mm), 1.4 µg/ml (2 mm) and 0.5 µg/ml (4 mm), respectively.
CONCLUSIONS: Under ex vivo hyperthermic conditions, cisplatin diffused into human lung tissue. The median penetration depth of the cisplatin was approximately 3-4 mm. The penetration of cisplatin into lung tissue may affect the local therapy of residual tumour cells on the lung surface using hyperthermic intrathoracic chemotherapy perfusion in patients with malignant pleural tumours.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Chemotherapy perfusion; Cisplatin; Hyperthermic perfusion; Penetration depth

Mesh:

Substances:

Year:  2014        PMID: 24872472     DOI: 10.1093/ejcts/ezu217

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

Review 1.  The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.

Authors:  Pietro Bertoglio; Vittorio Aprile; Marcello Carlo Ambrogi; Alfredo Mussi; Marco Lucchi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

2.  Debulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) for lung cancer.

Authors:  Marcello Migliore
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

3.  Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma.

Authors:  Marcello Migliore; Michael Ried; Laureano Molins; Marco Lucchi; Marcello Ambrogi; Tamas F Molnar; Hans-Stefan Hofmann
Journal:  Ann Transl Med       Date:  2021-06

Review 4.  Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies.

Authors:  Till Markowiak; Christopher Larisch; Hans-Stefan Hofmann; Michael Ried
Journal:  Ann Transl Med       Date:  2021-06

Review 5.  Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis.

Authors:  Hua Zhou; Wei Wu; Xiaoping Tang; Jianying Zhou; Yihong Shen
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  Assessment of concentration and penetration depth of cisplatin in human lung tissue after decortication and hyperthermic exposure.

Authors:  Christopher Larisch; Till Markowiak; Elena Loch; Christian Großer; Patrick J Bednarski; Karolina Mueller; Hans-Stefan Hofmann; Michael Ried
Journal:  Ann Transl Med       Date:  2021-06

7.  Protocol of a retrospective, multicentre observational study on hyperthermic intrathoracic chemotherapy in Germany.

Authors:  Till Markowiak; Michael Koller; Florian Zeman; Gunnar Huppertz; Hans-Stefan Hofmann; Michael Ried
Journal:  BMJ Open       Date:  2020-07-20       Impact factor: 2.692

8.  Exposure to cisplatin in the operating room during hyperthermic intrathoracic chemotherapy.

Authors:  Till Markowiak; Michael Ried; Christopher Larisch; Dennis Nowak; Hans-Stefan Hofmann; Stefan Rakete
Journal:  Int Arch Occup Environ Health       Date:  2021-06-30       Impact factor: 3.015

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.